TypeOnline Course
Student Enrolled2
Price$390 / Rs. 19500
Book Now
biosimilar course




Content Deliverables

Course Syllabus

Admission Process

Course Code: KPE-C-22

Course Title: KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management

Course Objective: Working Professionals & B.Pharm/D.Pharm/ B.Sc/ Any graduates or those who are in 3rd / final year of those courses, who want to make career in biopharmaceutical marketing, business development and regulatory affairs, can pursue the course.

Nature of the Course: Distance & e-Learning

Course Description:This online course – KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management training course utilizes interactive learning tools to guide each participant through the steps of the biotech and biosimilar drugs development process and regulation. The course is designed to challenge users to apply what they have learned through the use of interactive exercises, reflection questions, expert live chat and a final assessment at the end of the course.

The course can be completed at any pace, allowing the user to stop and start at their leisure.

Features of the Course:

1. Comprehensive study material covering all important aspects of Biosimilar regulation.

2. Understanding/ Decision Making/ Strategy Creation in the field of Biosimilar regulation.

3. Live Pharma  Case Study –  File for easy understanding in biologics-biosimilar regulations and its implications.

4. Specialized modules on demand

5. Certificate will be issued at the end of the course.

1 Month

Course Content Deliverables:

1. Printable Module can be downloaded by visiting to your dashboard.

2. Access the E-Modules online with user id and password.

3. Attend e-lectures.

4. Access to case study file online

5. All e-study material contains self assessment computer based test.

6. Flexible online final examination.

Printable Modules 

Module 1 Drug Discovery and Development Process
Module 2 Biopharmaceutical – Detailed Understanding 
Module 3 Biosimilar 
Module 4 Biosimilar Development Process
Module 5 Biopharmaceutical Industry 
Module 6 EU Biosimilar guidelines
Module 7 Biosimilar guidelines in different regions 
Module 8 Licensing and Technology Transfer in Biopharmaceutical Industry 
Module 9 Biopharma Case Studies

Other than books, you will also get the online modules – electures, case studies etc. which you can access by login with your access credentials. 

Biologic & Biosimilar Regulation and Registration course is structured as follows:

  • Biotech Drug Development Process
    Overview of the development of a biotech product – clarify the difference between synthetic drugs, biologics and biotech products .
  • Biotech Regulation – Key Understanding
    US drugs vs. Biologics Law: Understand the differences in regulatory philosophy between small molecules and biotech product regulation
  • Preclinical and Clinical Research Design
    An examination of preclinical and clinical research designs. Emphasis is on identifying and addressing challenges associated with elements of good laboratory and clinical practice and qualifying and managing a laboratory for a clinical trial. Discussion covers best practices for planning research and collecting, analyzing, and reporting data from drug/device development studies.
  • Analytical techniques for the Biotech Drugs
    Understand the need for using a range of analytical methods in the characterization of biotech product.
  • Product Life Cycle Approval, Production, and Marketing for Bio-pharmaceuticals
    An in-depth study of the product life cycle for medical devices and implants and pharmaceuticals. Focus is on the various stages within the life cycle from conceptualization of a product pipeline in research and development through postmarket surveillance and production. Topics include regulatory submission, approval, production, and the postmarket environment for both drugs and devices. Challenges surrounding the approval and naming of follow-on biologics are addressed. Discussion also covers combination medicines, the stages of a drug pipeline and risk assessment at each stage, and the decreasing productivity of the drug pipeline. The role of a contract research organization in testing and approval is explained, and the nature of the support services they provide to the biotechnology and devices industry is explored.
  • Global Biotechnology Business
    Topics include international biotechnology issues, global harmonization efforts, and the cultural impact of biotechnologies. Discussion also covers domestic and International business considerations and international regulatory requirements.

Practical Case Studies – Applications of Biotech Regulatory Affairs
A capstone study of regulatory affairs related to the biotechnology industry that integrates knowledge and skills gained from previous study.

  • Introduction to Global biopharmaceutical Industry. Overview of General Regulation.
  • Biotech Drug Discovery and Development Process
  • Biotech Drugs Classification. Important classes.
  • Introduction to Biotech Industry – Global and Indian. Leading Biotech companies and their product and pipeline analysis
  • Regulation in Biotech Industry
  • Overview of patent in biotech industry.
  • Introduction to Biosimilar. Meaning of Biosimilar vs. Follow on biologics.
  • Difference between biosimilar and generic drugs.
  • Key important issues in Biotech and biosimilar product manufacturing.
  • GMP requirements in biotech industry.
  • General approval process of biosimilar products.
  • Biosimilar Development project management – timeline creation with business outcome

Country specific regulation  in Biosimilar Products –

  • Biotech and Biosimilar regulation in US
  • Biotech and Biosimilar regulation in EU
  • Major differences in US and EU
  • Biosimilar regulation and registration in India
  • Biosimilar policies in the UK, Use of biosimilars in Europe, EMEA regulation on biosimilar
  • Registration of biosimilar in other different countries


Frequently asked questions

Read FAQs


Course Flow and Timeline

Section 1Introduction to Biopharmaceuticals
Lecture 1Introduction: Biopharmaceuticals
Lecture 2Classification & Detailed Understanding on Biopharmaceuticals
Lecture 3Introduction to Biosimilar
Lecture 4Chemical Drugs Vs. Biologic Drugs
Lecture 5Principle of Naming of Biologics
Section 2Global Biopharmaceutical Market
Lecture 6Current Trends in Biopharmaceutical Market
Lecture 7Dynamics of Biopharmaceutical Market
Lecture 8Challenges of Biopharmaceutical Industry
Lecture 9Biopharmaceutical Market Segmentation
Lecture 10Market Share of Different Class of Biopharmaceuticals
Lecture 11Blockbuster Biologic - Classifications, Indications, Global Sales
Section 3Detailed Understanding of different therapeutic classes of Biologics
Lecture 12Recombinant Proteins
Lecture 13Monoclonal Antibodies
Lecture 14Synthetic Immunomodulators
Lecture 15Vaccines
Section 4Biopharmaceutical Regulatory Approval Process
Lecture 16New Biopharmaceutical Approval process Vs. Bissimilar Vs. New Molecule Vs. Generic Drug Approval Process
Lecture 17Biologic License Application (BLA)
Lecture 18Biosimilar Approval process
Lecture 19Difference : Drugs Vs. Biopharmaceutical Approval process
Lecture 20Nomenclature of biosimilars
Lecture 21Vaccine Development Process
Lecture 22Pricing and cost effectiveness of biosimilars
Lecture 23Exclusivity Protections for Biopharmaceuticals
Lecture 24Risk Evaluation and Mitigation Strategy (REMS)
Lecture 25Learning from New Drug Approvals - 2016
Lecture 26PDUFA & BsUFA For Biologics
Lecture 27Review : 351(a) vs. 351(k) pathway
Section 5Biosimilar Manufacturing Process
Lecture 28Stages of Biosimilar development
Lecture 29Challenges in manufacturing of biosimilar
Lecture 30Concept of Reference Biologics
Lecture 31Detailed Manufacturing Process
Lecture 32Concept of Interchangeability in Biosimilar Development
Lecture 33Studies required for approval of biosimilar
Section 6Biopharmaceutical Patents - Biosimilar Entry / Exclusivity - Case Learnings
Lecture 34Practical Training on understanding of Biopharmaceutical Patent
Lecture 35Biopharmaceutical Exclusivity / protections
Lecture 36Patent Protection Small Molecules Vs. Innovator Biologics
Lecture 37Regulatory Exclusivity for Small Molecules Vs. Biosimilars
Lecture 38Steps Know How & Key Points - Patent Application
Lecture 39Fundamental Understanding of Patent, Trademark Licensing and related terminology
Section 7Principles for Development of Similar Biologics
Lecture 40Selection of Reference Biologics
Lecture 41Manufacturing Process Development for Biosimilar
Lecture 42Quality Based Considerations for Similar Biologics
Lecture 43Data Requirements for Preclinical Studies
Lecture 44Post-Market Data for Similar Biologics
Section 8Biosimilar Guidelines in Different Regions
Lecture 45WHO Regulatory Guidelines
Lecture 46European Union (EMA)
Lecture 47United States of America (US FDA)
Lecture 48Japan - PMDA
Lecture 49Korea (KFDA)
Lecture 50Canada (Health Canada)
Lecture 51China - SFDA
Lecture 52India (Central Drugs Standard Control Organization)
Lecture 53Jordan (Jordan Food and Drug Administration)
Lecture 54Middle East
Section 9Biosimilar Development to Commercialization : Case Studies
Lecture 55Biosimilar Development Timeline
Lecture 56Case Study New mAB approval: Avelumab for metastatic Merkel Cell Carcinoma (mMCC)
Section 10Biopharmaceutical Strategic Management
Lecture 57Patents Vs. exclusivity
Lecture 58Regulatory Strategies in different phases of Clinical Trial
Lecture 59Drug Repurposing
Lecture 60Pay For Delay Strategy
Lecture 61Compulsory Licensing
Lecture 62Technology Licensing
Lecture 63In-Licensing Vs. Outlicensing
Lecture 64Leading Biologic Company's Analysis : Strategic Point of view
Lecture 65Strategic alliance Termination / Failure in strategic alliances in biopharmaceutical industry
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,